Volume 3, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Of 115 patients treated for amebiasis, 67 were given fumagillin and 48, oxytetracycline. Patients with dysentery are considered separately because of differences in severity of illness, the development of extra-intestinal lesions, slower response and occurrence of relapses while still hospitalized.

Among 13 patients with dysentery receiving fumagillin, two developed hepatic abscess while under treatment. One of the patients with abscess died although receiving concomitant chloroquine. The other recovered after change of therapy to oxytetracycline and chloroquine. Two had recurrence of amebae while still hospitalized.

Sixteen patients with dysentery received oxytetracycline. Two developed hepatic abscess on treatment and one presumably had an unrecognized abscess on admission. The latter died on the sixth day of oxytetracycline therapy. Each of the remaining two received concomitant chloroquine. One recovered rapidly; the other died.

Of 86 patients with nondysenteric amebiasis, 54 were treated with fumagillin and 32 with oxytetracycline. On adequate dosage, there were no recurrences in either group during a minimal post-treatment period of 4 weeks in the hospital. Excluding the side effects of fumagillin, there were no significant differences in parasitologic or clinical response.

The environmental conditions to which these patients were exposed after release from the hospital are such as to render impossible an accurate evaluation of cure rates on the basis of prolonged follow-up.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error